Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiao Liu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Zhen Zhou

    School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia

    9 shared publications
  • Xiaohui Zeng

    Department of Nuclear Medicine, The Second Xiangya Hospital of Central South University, Changsha, China

    8 shared publications
  • Lidan Yi

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    7 shared publications
  • Xia Luo

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    7 shared publications
  • Xiaomin Wan

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

    7 shared publications
  • Xiaohui Zeng

    Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China

    6 shared publications

Latest Publications

  • Open Access

    Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective

    by Chaohao Shi, Yang Wang, Chongqing Tan, Xiaohui Zeng, Qiao Liu

    Background: Patients with severe asthma, particularly those with an eosinophilic phenotype, face a limited array of treatment options. The Mepolizumab Efficacy in Patients with Severe Asthma (MENSA) trial (clinicaltrials.gov NCT03562195) has underscored the potential therapeutic benefits of mepolizumab as an adjunctive treatment for this patient group. However, the high cost of mepolizumab therapy presents significant economic challenges that may impede its widespread adoption in China. This study aims to assess the cost-effectiveness of mepolizumab from a societal perspective within the Chinese population suffering from severe asthma. Methods: A Markov model spanning a lifetime horizon and employing a 2-week cycle was constructed. The model incorporated clinically significant exacerbations (CSEs) rates from the MENSA trial, along with asthma mortality rates, costs, and health state utilities, sourced from a broad spectrum of literature and national databases. Both costs and effectiveness outcomes were discounted annually at 5%. Incremental cost-effectiveness ratios (ICERs) were calculated as the primary model output and compared to a willingness-to-pay (WTP) threshold range of $15,217 to $38,042 per quality-adjusted life-years (QALY). The model’s robustness was evaluated through sensitivity analyses. Results: The base-case analysis indicated an ICER of $848.79 per QALY for mepolizumab, fall below the lower limit of the predefined WTP threshold. Subgroup analyses confirmed this finding across different subpopulations. Deterministic sensitivity analyses showed that mepolizumab’s ICER remained below the lower limit of the predefined WTP threshold even under significant parameter variations. Probabilistic sensitivity analyses further demonstrated mepolizumab’s cost-effectiveness advantage over placebo. Conclusion: Our study concluded that mepolizumab is a cost-effectiveness treatment option for severe asthma in China, applicable across various patient subgroups. This finding is crucial for healthcare decision-makers in China, where balancing cost and health outcomes is essential due to limited resources.

  • Open Access

    Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases

    by Ziying Zhao, Maolin Chen, Jiuzhou Du, Yanan Zhao, Liling Zhao, Li Fang, Qiao Liu

    Brain metastases (BrMs) frequently manifest in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the optimal treatment approach for these individuals remains controversial. This study aimed to evaluate the cost-effectiveness of adding pemetrexed-platinum chemotherapy to first-line gefitinib in EGFR-mutant NSCLC patients with BrMs, considering the perspective of the Chinese healthcare system. Constructing a Markov model, we simulated disease progression over a 10-year horizon in 4-week intervals. The model included three main health states: progression-free survival (PFS), progressive disease (PD), and death, along with a temporary PFS health state. Transition probabilities were estimated based on the data from the GAP BRAIN trial. Costs and utilities were collected from local public database and literature. One-way and probabilistic sensitivity analyses were employed to assess the robustness of the model. In the base case analysis, adding pemetrexed-platinum chemotherapy to first-line gefitinib resulted in an incremental effectiveness of 0.59 quality-adjusted life years (QALYs) and an increase in healthcare costs by $12,298.51. Consequently, the incremental cost-effectiveness ratio (ICER) amounted to $24,887.67/QALY, which fell below the prespecified willingness-to-pay (WTP) threshold of $37,654.50 per QALY. Deterministic sensitivity analysis indicated that, apart from the utility value of the PFS health state of the gefitinib plus chemotherapy (GPP) group, other parameters exerted minimal influence on the results. The probabilistic sensitivity analysis demonstrated that, at the predefined WTP threshold, the combination of gefitinib and chemotherapy was a cost-effective treatment strategy. Adding pemetrexed-platinum chemotherapy to first-line gefitinib for EGFR-mutant NSCLC patients with BrMs in China represented a cost-effective treatment strategy from the perspective of the Chinese healthcare system.


  • Comparative efficacy and safety of oral hypoglycaemic drugs as adjunctive therapy in the management of type 1 diabetes mellitus: A systematic review and meta‐analysis

    by Dong Wu, Xiaowu Wang, Qiao Liu, Xia Luo

    Aims: To evaluate the efficacy and safety of oral hypoglycaemic drugs (OHDs) as an adjunct to insulin therapy in patients with type 1 diabetes mellitus (T1DM), addressing the need for optimized glycaemic control and reduced insulin dependency. Materials and Methods: A systematic literature search was conducted across PubMed, Embase and the Cochrane Library to identify randomized clinical trials (RCTs) published up to October 31, 2024. Primary outcomes included changes in glycated haemoglobin (HbA1c) and hypoglycaemia risk. Secondary endpoints assessed six efficacy and seven safety measures using meta‐analysis. Treatment effects were quantified using weighted mean difference (WMD) and risk ratios (RRs) with 95% confidence intervals (CIs). Subgroup and indirect comparisons were performed to explore variations across patient demographics and drug classes. Results: The meta‐analysis included 51 RCTs with 8664 participants. Overall, compared with placebo, OHDs demonstrated significant reductions in HbA1c (WMD −0.32%, p < 0.001), fasting plasma glucose (WMD −0.91 mmol/L, p < 0.001), postprandial plasma glucose (WMD −2.08 mmol/L, p < 0.001), daily insulin dosage(WMD −4.88 IU/day, p < 0.001) and body weight (WMD −1.89 kg, p < 0.001), while improving the percentage time in the target glucose range of 3.9–10.0 mmol/L (WMD 6.04%, p = 0.04). However, no significant change was observed in BMI (WMD −0.18 kg/m 2 , p = 0.08). Compared with placebo, OHDs did not increase the risk of hypoglycaemia (RR 1.01, p = 0.08), severe hypoglycaemia (RR 0.95, p = 0.73) or nocturnal hypoglycaemia (RR 0.97, p = 0.24), but were associated with elevated risks of serious adverse events (RR 1.30, p = 0.005), discontinuation due to adverse events (RR 1.88, p < 0.001), genital tract infection (RR 3.30, p < 0.001), gastrointestinal side effects (RR 1.98, p < 0.001) and ketoacidosis (RR 3.14, p < 0.001). Indirect comparisons favoured alpha glucosidase inhibitor (AGI) over thiazolidinediones for HbA1c reduction (mean difference −0.46%, p < 0.001). Subgroup analysis revealed greater fasting glucose reduction in adults compared to children/adolescents (WMD −1.15 mmol/L vs. −0.26 mmol/L, p of group difference = 0.02). Conclusions: OHDs as adjunctive therapy in T1DM significantly improve glycaemic control and reduce insulin requirements. However, their use is associated with notable safety concerns, particularly ketoacidosis and other adverse events. Clinicians must conduct thorough risk assessments and tailor treatment plans to individual patient profiles to balance efficacy and safety. Future research should focus on long‐term outcomes and strategies to mitigate adverse effects.


  • Open Access

    Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    by Lidan Yi, Qiao Liu, Chongqing Tan, Xiaomin Wan, Xia Luo, Yinbo Li, Haiying Li, Xiaohui Zeng

    Objective: To assess the cost-effectiveness of adding daratumumab to carfilzomib and dexamethasone (KdD) in patients with relapsed or refractory multiple myeloma (RRMM). Materials and Methods: A Markov model was established to estimate health and economic outcomes of carfilzomib and dexamethasone (Kd) with or without daratumumab for RRMM patients over a lifetime horizon. The patients and intervention of the two arms were modeled according to the CANDOR trial. Costs were collected from the Chinese health system perspective. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to evaluate the robustness of our conclusions. Results: Compared with the Kd arm, KdD achieved an additional 0.537 quality-adjusted life-years (QALYs) at an incremental cost of $138,084, resulting in an incremental cost-utility ratios (ICURs) of $257,319 per QALY. Uncertainty analyses revealed that the model is robust to all the input parameters. Conclusion: From the Chinese healthcare system perspective, adding daratumumab to the Kd regimen for patients with RRMM appears to lack cost-effectiveness. Exploring alternative avenues such as negotiating for a more favorable price or introducing a financial assistance program dedicated to daratumumab and/or carfilzomib could prove to be an effective strategy in enhancing accessibility of this combination.


  • Open Access

    Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis

    by Juan Peng, Huiling Xu, Qiao Liu

    Background: This study aims to compare the cost-effectiveness of sintilimab in combination with chemotherapy, with or without bevacizumab biosimilar IBI305, versus chemotherapy alone for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) who have progressed on tyrosine-kinase inhibitor (TKI) treatment from the perspective of the Chinese healthcare system. Methods: 10-year Markov model was developed using a 21-day cycle length. Transition probabilities were derived from the ORIENT-31 trial, while cost and health state utilities were obtained from publicly databases, local hospitals, and published literature. Incremental cost-effectiveness ratios (ICERs) were calculated as the primary model output and compared to a willingness-to-pay (WTP) threshold range of $15,289.34 to $38,223.34 per quality-adjusted life-years (QALY). Sensitivity analyses were performed to assess the robustness of the model. Results: In the base-case analysis, sintilimab plus IBI305 and chemotherapy had an ICER of $53,266.32/QALYs, exceeding the upper WTP threshold. Sintilimab plus chemotherapy had an ICER of $15,329.11/QALY, slightly above the lower WTP threshold. Subgroup analysis yielded consistent results. Deterministic sensitivity analyses found no ICER for sintilimab plus chemotherapy beyond the upper WTP threshold. Most model input changes did not decrease the ICER of sintilimab plus IBI305 and chemotherapy below the upper WTP threshold. Probabilistic sensitivity analyses further demonstrated the cost-effectiveness superiority of sintilimab plus chemotherapy over sintilimab plus IBI305 and chemotherapy. Conclusion: This study supports the cost-effectiveness of using sintilimab in combination with chemotherapy. Nevertheless, the cost-effectiveness of combining sintilimab with IBI305 and chemotherapy in this particular patient group may be lacking.


  • Open Access

    Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China

    by Shuo Tian, Yuping Yang, Shenglan Tan, Jiani Luo, Chuanyu Yang, Qiao Liu, Yujin Guo

    Purpose: This study assesses the cost-effectiveness of rimegepant for the on-demand acute treatment of migraine in the Chinese population, focusing on headache relief within a 2 h timeframe. Utilizing data from Phase III clinical trials on rimegepant involving Asian populations, this analysis aims to provide essential insights for healthcare decision-making in the context of migraine management in China.Patients and methods: Employing a decision tree model, this research evaluates the cost-effectiveness of rimegepant over a concise 2 h period, exclusively considering its direct market price of 219.00 CNY per dose for on-demand, single-use treatment upon approval in China. This model is based on pain relief outcomes from a clinical trial, categorizing health outcomes by the achievement of pain freedom and alleviation from the most bothersome symptom within two hours post-administration.Results: The study unveils that rimegepant adds 0.0018 quality-adjusted life days (QALD) with an incremental cost-effectiveness ratio (ICER) of 122,166.07 CNY/QALD. Against a daily cost-effectiveness threshold derived from the 2023 per capita GDP of China (734.45 CNY/day), rimegepant falls short of proving its cost-effectiveness. A significant price reduction to approximately 1.32 CNY per dose is required for rimegepant to be considered cost-effective within this framework. Furthermore, a series of sensitivity analyses were conducted to validate the robustness of these results.Conclusion: While rimegepant shows clinical efficacy in providing rapid relief from migraine symptoms, its current pricing exceeds the threshold for cost-effectiveness in the Chinese healthcare setting. This study underscores the need for price adjustments to enhance the accessibility and economic viability of new migraine treatments.


  • Open Access

    First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis

    by Lidan Yi, Zhen Zhou, Xiaohui Zeng, Chongqing Tan, Qiao Liu

    Objective: To determine the cost-effectiveness of imported immune checkpoint inhibitors (ICIs) such as atezolizumab and durvalumab, and domestic ICIs like serplulimab and adebrelimab, in combination with chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) in China.Methods: Using a 21-day cycle length and a 20-year time horizon, a Markov model was established to compare the clinical and economic outcomes of five first-line ICIs plus chemotherapy versus chemotherapy alone, as well as against each other, from the perspective of the Chinese healthcare system. Transition probabilities were estimated by combining the results of the CAPSTONE-1 trial and a published network meta-analysis. Cost and health state utilities were collected from multiple sources. Both cost and effectiveness outcomes were discounted at a rate of 5% annually. The primary model output was incremental cost-effectiveness ratios (ICERs). A series of sensitivity analyses were preformed to assess the robustness of the model.Results: In the base-case analysis, the addition of first-line ICIs to chemotherapy resulted in the ICERs ranged from $80,425.31/QALY to $812,415.46/QALY, which exceeded the willing-to-pay threshold set for the model. When comparing these first-line immunochemotherapy strategies, serplulimab plus chemotherapy had the highest QALYs of 1.51286 and the second lowest costs of $60,519.52, making it is the most cost-effective strategy. Our subgroup-level analysis yielded results that are consistent with the base-case analysis. The sensitivity analysis results confirmed the validity and reliability of the model.Conclusion: In China, the combination of fist-line ICIs plus chemotherapy were not considered cost-effective when compared to chemotherapy alone. However, when these fist-line immunochemotherapy strategies were compared with each other, first-line serplulimab plus chemotherapy consistently demonstrated superiority in terms of cost-effectiveness. Reducing the cost of serplulimab per 4.5 mg/kg would be a realistic step towards making first-line serplulimab plus chemotherapy more accessible and cost-effective.


  • Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing

    by Lidan Yi, Xiaohui Zeng, Zhen Zhou, Qiao Liu

    Introduction This study sought to investigate the affordable price of sotorasib among patients with previously treated advanced KRASG12C-mutant non-small cell lung cancer (NSCLC) through a cost-effectiveness analysis from the perspectives of both the Chinese healthcare system and the patients. Methods We developed a Markov model spanning a 20-year time horizon with a cycle length of 21 days. Our data were derived from the CodeBreaK 200 clinical trial, supplemented with published literature, publicly available national databases, and local hospitals. The primary outcomes were the affordable prices of sotorasib which would result in the incremental cost-effectiveness ratios (ICERs) of sotorasib relative to docetaxel below the preset willing-to-pay (WTP) threshold. Sensitivity analyses were performed to evaluate the model's robustness. Results At the national level, from the perspective of the Chinese healthcare system and patients, the price of sotorasib should be lower than US$0.04673 and $0.03231, respectively, to make it affordable, which is equivalent to $1346 and $931 per box (120 mg × 240 pieces). At the provincial level, the price ceiling of sotorasib/mg fluctuated between $0.04084 to $0.08061 from the Chinese healthcare system’s perspective and between $0.02642 to $0.06620 from the patients’ perspective. Probabilistic sensitivity analyses revealed that, as the price of sotorasib decreased, its likelihood of being cost-effective increased. Conclusion Sotorasib might be a cost-effective therapy in China. The pharmaco-economic evidence generated from this study has significant implications not only for guiding the drug pricing of the upcoming sotorasib but also for determining the reimbursement ratio for its potential inclusion in the National Reimbursement Drugs List in the future.

  • Open Access

    A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis

    by Shuo Tian, Haitao Zhong, Mengyue Yin, Pei Jiang, Qiao Liu

    Purpose: This study aims to conduct a comprehensive cost-effectiveness comparison between novel oral anticoagulants (NOACs) and warfarin in Chinese patients with left ventricular thrombosis (LVT). By incorporating the impact of volume-based procurement (VBP) policy for pharmaceuticals in China, this analysis intends to provide crucial insights for informed healthcare decision-making. Patients and Methods: A Markov model was employed to simulate the disease progression of LVT over a 54-week time horizon, using weekly cycles and six mutually exclusive health states. The model incorporated transition probabilities between health states calculated based on clinical trial data and literature sources. Various cost and utility parameters were also included. Additionally, a series of sensitivity analyses were conducted to address parameter variations and associated uncertainties. Results: The study finding suggest that from the perspective of Chinese healthcare, the majority of brand-name drug (BND) NOACs generally lack cost-effectiveness when compared to warfarin. However, when considered the VBP policy, NOACs, particularly rivaroxaban, prove to be more cost-effective than warfarin. Rivaroxaban provided an additional 0.0304 quality-adjusted life years (QALYs) per patient and reduced overall medical costs by 9095.73 CNY, resulting in an incremental cost-effectiveness ratio (ICER) of − 298,786.20 CNY/QALY. Sensitivity analysis indicated a 78.4% probability of any NOACs being more cost-effective compared to warfarin. However, specifically considering NOACs under the VBP policy, the likelihood of them being more cost-effective approached 90%. Conclusion: Taking into account Chinese pharmaceutical procurement policies, the findings highlight the superior efficacy of NOACs, especially rivaroxaban, in enhancing both the quality of life and economic benefits for Chinese LVT patients. NOACs present a more cost-effective treatment option, improving patient quality of life and healthcare cost efficiency compared to warfarin.


  • Open Access

    Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens

    by Lan-Fang Li, Ran Qi, Tian-Tian Wei, Lei Feng, Xin Zhang, Qiao Liu

    Purpose: The IPSOS study provided evidence supporting the efficacy and tolerability of first-line atezolizumab compared to single-agent chemotherapy for non-small-cell lung cancer (NSCLC) patients ineligible for treatment with a platinum-containing regimen. This study aimed to assess the cost-effectiveness of atezolizumab specifically in this population, considering the perspective of the Chinese healthcare system. Patients and Methods: In this analysis, a three-state Markov model was utilized. The survival data were derived from the IPSOS clinical trial. Direct medical costs and utility values were collected from national authoritative database and published literature. The primary outcomes were costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER). To ensure the robustness of our model, both one-way and probabilistic sensitivity analyses were conducted. Results: Atezolizumab monotherapy led to an increase in costs of $4139.23 compared to single-agent chemotherapy. Additionally, it resulted in a gain of 0.14 QALYs, leading to an ICER of $29,365.79 per QALY, which was below the willingness-to-pay threshold of $36,066 per QALY used in the model. One-way sensitivity analyses revealed cost of atezolizumab and utility of progressive disease (PD) as major influencing factors for ICER. Furthermore, probabilistic sensitivity analyses confirmed our base-case results. Conclusion: From the perspective of the Chinese healthcare system, atezolizumab emerges as a cost-effective choice for the first-line treatment of NSCLC patients ineligible for platinum-based chemotherapy.